BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 15330178)

  • 1. Can recurrence of meningiomas be predicted?
    Kalala JP; Benoit D; De Ridder L
    Anticancer Res; 2004; 24(4):2319-24. PubMed ID: 15330178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary resected meningiomas: relapses and proliferation markers.
    Kalala JP; Caemaert J; De Ridder L
    In Vivo; 2004; 18(4):411-6. PubMed ID: 15369177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
    Roser F; Samii M; Ostertag H; Bellinzona M
    Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCNA, Ki-67 and hTERT in residual benign meningiomas.
    Maes L; Kalala JP; Cornelissen M; De Ridder L
    In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
    Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
    Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting recurrence of intracranial meningiomas. A multivariate clinicopathologic model--interim report of the New York University Medical Center Meningioma Project.
    Miller DC
    Neurosurg Clin N Am; 1994 Apr; 5(2):193-200. PubMed ID: 8032222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive meningiomas in relation to high proliferating potential.
    Suwa T; Kawano N; Kameya T; Ito H; Oka H; Yada K
    Noshuyo Byori; 1993; 10(1):63-7. PubMed ID: 7693228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
    Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
    Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value].
    Korshunov AG; Shishkina LV; Golanov AV
    Arkh Patol; 2002; 64(1):29-33. PubMed ID: 11889696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S100A5: a marker of recurrence in WHO grade I meningiomas.
    Hancq S; Salmon I; Brotchi J; De Witte O; Gabius HJ; Heizmann CW; Kiss R; Decaestecker C
    Neuropathol Appl Neurobiol; 2004 Apr; 30(2):178-87. PubMed ID: 15043715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does protein expression predict recurrence of benign World Health Organization grade I meningioma?
    Kärjä V; Sandell PJ; Kauppinen T; Alafuzoff I
    Hum Pathol; 2010 Feb; 41(2):199-207. PubMed ID: 19801161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
    Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
    Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study on the recurrence of meningiomas: correlating factors for the recurrence and therapeutic prognosis of meningiomas].
    Miyagami M; Miyagi A; Kido G; Tsubokawa T
    No Shinkei Geka; 1994 May; 22(5):421-8. PubMed ID: 8196827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
    Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
    APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hTERT protein as a marker for malignancy in meningiomas.
    Kalala JP; Maes L; Vandenbroecke C; de Ridder L
    Oncol Rep; 2005 Feb; 13(2):273-7. PubMed ID: 15643510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the proliferating cell nuclear antigen and clinicopathological features in intracranial meningiomas.
    Kim CH; Cheong JH; Bak KH; Kim JM; Oh SJ
    J Clin Neurosci; 2001 May; 8 Suppl 1():44-8. PubMed ID: 11386825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferating cell nuclear antigen (PCNA) and nucleolar organizer regions (NORs) in benign, atypical and malignant meningiomas.
    Lee MC; Kang MW; Yang BS; Park CS; Juhng SW; Jung S; Kim JH; Kim SH; Kang SS; Lee JH
    Noshuyo Byori; 1995; 12(2):133-9. PubMed ID: 8867694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-67 index as a predictive marker of meningioma recurrence following surgical resection.
    Mizrachi M; Hartley B; Saleem S; Hintz E; Ziemba Y; Li J; Goenka A; Schulder M
    J Clin Neurosci; 2024 Jun; 124():15-19. PubMed ID: 38631196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between malignant subtypes of meningioma and clinical outcome.
    Ko KW; Nam DH; Kong DS; Lee JI; Park K; Kim JH
    J Clin Neurosci; 2007 Aug; 14(8):747-53. PubMed ID: 17499508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of apparent diffusion coefficient with Ki-67 proliferation index in grading meningioma.
    Tang Y; Dundamadappa SK; Thangasamy S; Flood T; Moser R; Smith T; Cauley K; Takhtani D
    AJR Am J Roentgenol; 2014 Jun; 202(6):1303-8. PubMed ID: 24848829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.